Real-time Estimate Quote. Real-time Estimate Cboe BZX - 05/24 02:04:53 pm
53.265 USD   +0.73%
12:13pGLOBAL MARKETS LIVE : Broadcom, Airbnb, Roche, Toyota, Uber
10:48aWALL STREET STOCK EXCHANGE : Snap cut the rally short
10:36aMarketScreener's World Press Review : May 24, 2022
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer Reports Positive Results From Study Co-Administering Vaccines for Covid-19, Pneumococcal Disease

01/12/2022 | 07:22am EDT

By Matt Grossman

Pfizer Inc. said a Phase 3 study in which patients were administered Covid-19 vaccines and the company's Prevnar vaccine for pneumococcal disease at the same time led to positive top-line results.

In the study, responses elicited by the Prevnar vaccine for Covid-19 were similar whether or not the vaccine was given alongside a Covid-19 vaccine. The same was true for Covid-19 vaccination. The safety profiles of the shots were little changed compared with being administered separately, the company said.

Giving two vaccines at once could be a way to promote vaccine update, Pfizer said.

"As the Covid-19 vaccines and booster doses continue to be administered, we believe that healthcare providers have an opportunity to talk to their adult patients about other recommended vaccines in line with CDC guidance," the company said.

Pfizer created its Covid-19 vaccine alongside BioNTech SE.

Write to Matt Grossman at

(END) Dow Jones Newswires

01-12-22 0722ET

Stocks mentioned in the article
ChangeLast1st jan.
BELIEVE -2.92% 9.295 Real-time Quote.-43.34%
BIONTECH SE -4.56% 156.04 Delayed Quote.-36.69%
PFIZER, INC. 0.56% 53.18 Delayed Quote.-10.45%
All news about PFIZER, INC.
12:13pGLOBAL MARKETS LIVE : Broadcom, Airbnb, Roche, Toyota, Uber
10:48aWALL STREET STOCK EXCHANGE : Snap cut the rally short
10:36aMarketScreener's World Press Review : May 24, 2022
06:47aPfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-..
05:26aPfizer Sees Positive Results in Etrasimod Trials
01:08aChina's bet on homegrown mRNA vaccines holds back nation
05/23Pfizer says 3 COVID shots protect children under 5
05/23Wall Street rebounds with assist from banks, big tech
05/23What's next for COVID-19 vaccines for youngest US children
05/23GLOBAL MARKETS LIVE : Tesla, Kohl's, Apple, JPMorgan, Bank of America...
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 662 M - -
Net cash 2022 10 478 M - -
P/E ratio 2022 8,82x
Yield 2022 3,07%
Capitalization 297 B 297 B -
EV / Sales 2022 2,75x
EV / Sales 2023 3,58x
Nbr of Employees 79 000
Free-Float 58,2%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 52,88 $
Average target price 57,66 $
Spread / Average Target 9,04%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-10.45%296 704
JOHNSON & JOHNSON4.89%472 179
ROCHE HOLDING AG-14.40%273 052
ABBVIE INC.9.33%261 585
NOVO NORDISK A/S2.29%245 087